A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis


A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis
Slides from presentations at ASCO 2011

Verstovsek S et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Proc ASCO 2011;Abstract 6500.